SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

Baxter International Inc. (BAX) News

Track canonical SquawkNews coverage tagged to BAX, Baxter International Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol BAX Asset equity Sector Markets 90 days 15 Last 26.73 Updated Jul 31, 2026, 11:38 AM UTC Open live news feed
H Banks Upgrade AXTI, IP, PLXS, SAIA Banks upgrade multiple stocks EQUITY | Jul 31, 2026, 11:38 AM UTC H BAX Upgraded to Neutral BAX upgraded to Neutral from Sell EQUITY | Jul 31, 2026, 10:41 AM UTC H Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress Baxter International Inc. (NYSE: BAX ) stock is trading higher on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2026 guidance. • Baxter International shar EARNINGS | Jul 30, 2026, 03:34 PM UTC H BAX +16% after Q2 net sales above expectations ($2.96B vs $2.8B est) and management raising FY organic sales growth guide to +2-3% vs flat p BAX +16% after Q2 net sales above expectations ($2.96B vs $2.8B est) and management raising FY organic sales growth guide to +2-3% vs flat previously. FY EPS guide $1.95-2.15 ex-items vs prior guidance $1.85-2.05. Revenu EARNINGS | Jul 30, 2026, 01:54 PM UTC H BAX raises annual profit forecast BAX raises annual profit forecast EARNINGS | Jul 30, 2026, 01:38 PM UTC H Baxter rises 13% on Q2 revenue Baxter Q2 revenue climbs EQUITY | Jul 30, 2026, 11:42 AM UTC L BAX - Baxter Reports Second-Quarter 2026 Results BAX - Baxter Reports Second-Quarter 2026 Results EQUITY | Jul 30, 2026, 11:17 AM UTC H Baxter raises sales growth outlook Baxter raises full-year sales growth outlook EARNINGS | Jul 30, 2026, 11:16 AM UTC H Baxter International Raises FY2026 Adj EPS Guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 Est; Raises FY2026 Sales Guidance from $11.244B Baxter International (NYSE: BAX ) raises FY2026 Adj EPS guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 analyst estimate. Raises FY2026 sales outlook from $11.244 billion-$11.356 billion to $11.581 billion-$11.694 bill EARNINGS | Jul 30, 2026, 11:16 AM UTC H BAX Baxter RESULTS: Q2, Q2 ADJ EPS $0.54 vs. EST $0.37, Q2 REV $2.960B vs. EST $2.795B, Q2 Net Income $126M, Baxter Earnings Notes:, Outlook BAX Baxter RESULTS: Q2, Q2 ADJ EPS $0.54 vs. EST $0.37, Q2 REV $2.960B vs. EST $2.795B, Q2 Net Income $126M, Baxter Earnings Notes:, Outlook FY REV growth 3-4%, Outlook FY ADJ EPS $1.95-2.15 vs. EST $1.91 EARNINGS | Jul 30, 2026, 11:15 AM UTC L BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS EQUITY | Jul 28, 2026, 11:47 AM UTC L BAX Baxter: changes do not impact Co's previously issued Consolidated financial statements except for its segment disclosures BAX Baxter: changes do not impact Co's previously issued Consolidated financial statements except for its segment disclosures EQUITY | Jul 14, 2026, 08:20 PM UTC L BAX Baxter - shared corporate expenses to remain unallocated in segment reporting - SEC filing BAX Baxter - shared corporate expenses to remain unallocated in segment reporting - SEC filing REGULATION | Jul 14, 2026, 08:18 PM UTC L BAX Baxter - changes reportable segments to two segments effective Q2 2026 - SEC filing - Pharmaceuticals segment now reported within infusi BAX Baxter - changes reportable segments to two segments effective Q2 2026 - SEC filing - Pharmaceuticals segment now reported within infusion Therapies & platforms division - SEC filing REGULATION | Jul 14, 2026, 08:17 PM UTC L Evercore ISI Adjusts Price Target on Baxter International to $24 From $22 () -- Baxter International (BAX) has an average rating of hold and mean price target of $19.90, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firm EQUITY | Jul 06, 2026, 01:22 PM UTC